-
Inclisiran, sold
under the
brand name Leqvio, is a
medication used for the
treatment of high low-density
lipoprotein (LDL)
cholesterol and for the treatment...
-
announced that the US Food and Drug
Administration (FDA)
approved Leqvio (
inclisiran), a
small interfering RNA (siRNA)
therapy to
lower low-density lipoprotein...
- US and Europe:
patisiran (2018),
givosiran (2019),
lumasiran (2020),
inclisiran (2020 in
Europe with anti****ted US
approval in 2021), and vutrisiran...
-
inhibitors are
monoclonal antibodies for
refractory cases. (e.g. Evolo****ab,
Inclisiran) They are used in
combination with statins.
Probucol (withdrawn in several...
- PMID 18753623.
Santulli G,
Jankauskas SS,
Gambardella J (May 2021). "
Inclisiran: a new
milestone on the PCSK9 road to
tackle cardiovascular risk". Eur...
-
order to
acquire amongst other ****ets, the
cholesterol lowering therapy;
inclisiran. In
April 2020, the
company announced it
would acquire Amblyotech. In...
- hypercholesterolemia, who
require additional lowering of LDL cholesterol. More
recently Inclisiran has been
approved for the
treatment of HeFH
Although monoclonal antibodies...
- C10AX13 Evolo****ab C10AX14 Aliro****ab C10AX15
Bempedoic acid C10AX16
Inclisiran C10AX17 Evina****ab C10AX18
Volanesorsen C10BA01
Lovastatin and nicotinic...
-
available for
commercial application, and two siRNAs,
lumasiran (ALN-GO1) and
inclisiran, have been
submitted for new drug
application to the FDA.
Several siRNAs...
- 1D05-IgG2 (Merck), RG-7652 and LY3015014, as well as the RNAi
therapeutic inclisiran. PCSK9
inhibitors are
promising therapeutics for the
treatment of people...
